Pharma BD Deal Intelligence
Biogen entered into a definitive agreement to acquire TJ Biopharma's exclusive rights to felzartamab in the Greater China Region, giving Biogen exclusive worldwide rights to the asset. Felzartamab is being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases. TJ Bio receives a $100 million upfront payment and is eligible for up to $750 million in commercial and sales milestone payments (up to $20 million commercial and up to $730 million sales), for total potential consideration of up to $850 million, plus mid-single-digit to low-double-digit percentage royalties on potential net sales in the Greater China Region. Biogen expects to record the upfront payment as Acquired In-Process Research and Development expense in Q2 2026.
← Browse all deals · How we score deals
More: 2026 deals · Biogen Inc. deals · Immunology deals